Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Metabolex links with J&J unit

July 3, 2006 | A version of this story appeared in Volume 84, Issue 27

Metabolex and Johnson & Johnson's Ortho-McNeil unit have agreed to develop and commercialize Metabolex's two clinical compounds, metaglidasen and MBX-2044. Both are small molecules that treat metabolic diseases, including type 2 diabetes and obesity. Metabolex will get $40 million in financing and could receive up to $508 million if it achieves all milestones.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.